Then & Now: 20 Years and Still Going Strong
Then & Now: 20 Years and Still Going Strong
OCRF Board Member, Robin Zarel, Celebrates 20 Years as an Ovarian Cancer Survivor.
News
Supreme Court to Consider Two Birth Control Lawsuits
Supreme Court to Consider Two Birth Control Lawsuits
The Supreme Court recently announced that it will hear two cases involving insurance coverage for birth control. The Alliance weighed in on one of these cases, arguing that oral contraceptives are a proven way to prevent ovarian cancer and should therefore be made available to women who wish to reduce their risk. Our CEO Calaneet … Continued
Scientists Ask: Does Ovarian Cancer Have a Smell?
Scientists Ask: Does Ovarian Cancer Have a Smell?
George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has a smell. In diseases that affect our metabolism, we secrete smells that can be indicative of what … Continued
Partner Member Profile: Ovacome
Partner Member Profile: Ovacome
In 1999, Frieda Hooper was diagnosed with ovarian cancer. Frustrated with the lack of educational and supportive resources available, Hooper formed a support group for women with ovarian cancer in the Tampa Bay area, under the American Cancer Society. Rapidly growing in popularity, Ovacome started meeting independently of the American Cancer Society, eventually becoming an … Continued
OCRF Research Shows that Combining Targeted Agents is Effec...
OCRF Research Shows that Combining Targeted Agents is Effective Against Ovarian Cancer
New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer. The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial commentary. The research was funded in … Continued
Use of a Chemoresponse Assay Improves Clinical Outcomes
Use of a Chemoresponse Assay Improves Clinical Outcomes
Research published in the November 2013 issue of Gynecologic Oncology reports that the use of the chemoresponse assay ChemoFx can lead to improved clinical outcomes for women undergoing treatment for ovarian cancer. The goal of this clinical trial, which took nearly ten years to complete, was to determine the association of chemoresponse assay results with … Continued
Quality of life: Primary Debulking Surgery versus Neo-adjuv...
Quality of life: Primary Debulking Surgery versus Neo-adjuvant Chemotherapy
An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971). They compared the quality of life patients who had primary debulking surgery versus those who had neo-adjuvant chemotherapy, followed by surgery. The results, which are published in the journal Gynecologic Oncology, showed … Continued
Partner Member Profile: Sherie Hildreth Ovarian Cancer Foun...
Partner Member Profile: Sherie Hildreth Ovarian Cancer Foundation
In 2004, Sherie Hildreth was diagnosed with ovarian cancer. If the disease alone wasn’t frustrating enough, there was a lack of resources and what seemed like no other women to connect with in Oregon. During her treatment, Sherie noticed a lot of women did not have anyone to turn to, and wanted to create a … Continued
New Study find Hot Ovarian Cancer Cells are Easier to Kill
New Study find Hot Ovarian Cancer Cells are Easier to Kill
Oregon State University researchers have found that using nanotechnology with heat and cytotoxic drugs can kill up to 95% of ovarian cancer cells. While there is still additional research that needs to be done, the results of the initial study are promising for the future of ovarian cancer treatments. Read full article here.
New Clue in BRCA1 and BRCA2 Mutations
New Clue in BRCA1 and BRCA2 Mutations
A new study released in Lancet Oncology showed that abnormal levels of female hormones in the bloodstream may be why women with BRCA1 or BRCA2 mutations are at a higher risk for breast and ovarian cancer and not other cancers. UCL Department of Women’s Cancer completed the study that found different levels of the female hormones … Continued
DNA "Tags" Could Guide Treatment
DNA "Tags" Could Guide Treatment
A new study conducted by Cancer Research UK has identified chemical “tags” on DNA in patients’ tumors that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive. The research was published in Clinical Cancer Research. These tags, known as epigenetic markers, could be used to assess whether patients will … Continued
New Discovery of Inflammation Process of Some Ovarian Cance...
New Discovery of Inflammation Process of Some Ovarian Cancer Tumors Could Help Expand Treatment
A study led by Dr. Andrew Stephens from the Prince Henry’s Institute has discovered a process that is associated with inflammation in cancers. This discovery could lead to expanded treatment options for some types of ovarian cancer tumors. Monash Health, Hasanuddin University, Indonesia and Lincoln Research Centre, Christchurch also participated in the study which was … Continued